NOTICE: Citizendium is still being set up on its newer server, treat as a beta for now; please see here for more.
Citizendium - a community developing a quality comprehensive compendium of knowledge, online and free. Click here to join and contribute—free
CZ thanks our previous donors. Donate here. Treasurer's Financial Report -- Thanks to our content contributors. --

Escitalopram

From Citizendium
Jump to: navigation, search
This article is developing and not approved.
Main Article
Talk
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and not meant to be cited; by editing it you can help to improve it towards a future approved, citable version. These unapproved articles are subject to a disclaimer.

In psychiatry, escitalopram is a second-generation antidepressant for treating major depressive disorder. It is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition. [1]

Escitalopram is the S-enantiomer of racemic citalopram.[2]

History

Lexapro brand of escitalopram was approved by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 2002.[3]

Efficacy

According to a systematic review by the Cochrane Collaboration:[2]

"Some statistically significant differences favouring escitalopram over other antidepressive agents for the acute phase treatment of major depression were found, in terms of efficacy (citalopram and fluoxetine) and acceptability (duloxetine). There is insufficient evidence to detect a difference between escitalopram and other antidepressants in early response to treatment (after two weeks of treatment). Cost-effectiveness information is also needed in the field of antidepressant trials. Furthermore, as with most standard systematic reviews, the findings rely on evidence from direct comparisons. The potential for overestimation of treatment effect due to sponsorship bias should also be borne in mind."

Pharmacology

Administration

Distribution

Metabolism

Escitalopram is metabolised by cytochrome P-450 CYP3A4 and CYP2C19.

Excretion

Toxicity

Drug toxicity include:

External links

The most up-to-date information about Escitalopram and other drugs can be found at the following sites.


References

  1. Anonymous (2020), Escitalopram (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. 2.0 2.1 Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H et al. (2009). "Escitalopram versus other antidepressive agents for depression.". Cochrane Database Syst Rev (2): CD006532. DOI:10.1002/14651858.CD006532.pub2. PMID 19370639. Research Blogging.
  3. Drugs@FDA.
  4. van Gorp F, Whyte IM, Isbister GK (2009). "Clinical and ECG effects of escitalopram overdose.". Ann Emerg Med 54 (3): 404-8. DOI:10.1016/j.annemergmed.2009.04.016. PMID 19556032. Research Blogging.
  5. Covyeou JA, Jackson CW (2007). "Hyponatremia associated with escitalopram.". N Engl J Med 356 (1): 94-5. DOI:10.1056/NEJMc062840. PMID 17202465. Research Blogging.